Search clinical trials for: Post-ET Myelofibrosis

Total 586 results

Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Kartos Therapeutics, Inc.
Telios Pharma, Inc.

Recruiting

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

United States, Italy, Serbia, Poland, France, Austria, Bulgaria, Germany, Hungary, Spain
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
University of Ulm

Active, not recruiting

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)

Primary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MF

Germany
University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Ryvu Therapeutics SA

Not yet recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Myelofibrosis

Italy, Poland
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid Malignancy

China
University Hospital, Angers

Not yet recruiting

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes (PHEMOP)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

France
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Australia, New Zealand
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Myelofibrosis | Splenomegaly

United States
Ajax Therapeutics, Inc.

Not yet recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | PMF | Post-Essential Thrombocythemia Myelofibrosis | PPV-MF | PET-MF

United States
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Incyte Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Myelofibrosis

China
Fox Chase Cancer Center

Recruiting

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Essential Thrombocytosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

A New Blood Score for Myelofibrosis Staging (FIBROMOELLE)

Myeloproliferative Neoplasm
First Affiliated Hospital of Zhejiang University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; Second Affiliated... and other collaborators

Recruiting

18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.

Myelofibrosis

China
The First Affiliated Hospital of Xiamen University

Recruiting

68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

Primary Myelofibrosis

China
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, France, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Myelofibrosis

China
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of
University of Southern California
National Cancer Institute (NCI)

Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined Significance

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm | Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States
University of Alabama at Birmingham

Not yet recruiting

CD34 Selection Using the Automated CliniMACS Prodigy

Myelodysplastic Syndromes | Primary Myelofibrosis | AML | Lymphoid Malignancies | CML | ALL

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Myelofibrosis

China
University Hospital, Bordeaux

Recruiting

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC) (EpiC)

Myeloproliferative Neoplasm

France
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
Karyopharm Therapeutics Inc

Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (SENTRY-2)

Myelofibrosis | Moderate Thrombocytopenia

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Keros Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Iron Deficiency Anemia

Australia, Israel, Romania
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Real World Evidence of Fedratinib Effectiveness in MF (REALFed)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Italy
The University of Hong Kong
Novartis

Recruiting

Asian Myeloproliferative Neoplasm (MPN) Registry

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Hong Kong
Universitaire Ziekenhuizen KU Leuven

Recruiting

PEA in Functional Dyspepsia

Dyspepsia and Other Specified Disorders of Function of Stomach

Belgium
University of Rochester

Not yet recruiting

A Telehealth Advance Care Planning Intervention (TeleSICP)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myelodysplastic/Myeloproliferative Neoplasm

United States
Icahn School of Medicine at Mount Sinai
Dompé Farmaceutici S.p.A

Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF) | Post Essential Thrombocythemia Myelofibrosis (ET-MF) | Post Polycythemia Vera Related Myelofibrosis (PV-MF)

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Follicular Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid | Myelofibrosis | Burkitt Lymphoma | Marginal Zone Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Plasma Cell Leukemia | Myeloproliferative Neoplasm | Small Lymphocytic... and other conditions

United States
Assiut University

Not yet recruiting

Ruxolitinib in Patients With Myelofibrosis

Myelofibrosis
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
University Hospital, Angers

Not yet recruiting

Clonal Architecture of ASXL1-mutated Myelofibrosis (CLONEMF)

Myelofibrosis

France
Bristol-Myers Squibb

Recruiting

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Myelofibrosis

Austria
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Effect of Indication Based Blood Product Transfusion in Patients Undergoing Major Oncological Surgery

Blood Transfusion
The University of Hong Kong
Imago BioSciences,Inc.

Recruiting

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Myelofibrosis

Hong Kong
University of Utah

Recruiting

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

Myelofibrosis

United States
John Mascarenhas

Recruiting

Study of Canakinumab in Patients With Myelofibrosis

Primary Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | ET-MF | Post-polycythemia Vera Related Myelofibrosis | PV-MF

United States
Jacqueline Garcia, MD
AbbVie

Recruiting

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myeloproliferative Neoplasm

United States
Qilu Hospital of Shandong University

Recruiting

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Myelofibrosis

China

Search clinical trials for: Post-ET Myelofibrosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations